Ipilimumab for the treatment of cancer - Patent Overview (Last 5 years)
Predictive biomarkers for ctla-4 blockade therapy and for pd-1 blockade therapy is titled for one of the patents owned by H.Lee motif cancer institute wherein the PCT is filed in 2013.There are few other patents published recently around Ipilimumab compositions. To know in detail what is claimed in the patents and also in the embodiments in details, it is worth going through the patent overview.
This patent report provides a statistical overview of the specified technology/segment for the last five years.The claimed technology in the patent is segmented categorically and is the basis for insights into research and business.The report focuses on IP publication trends and the top 20 assignees - their technology trends and research breadth across various jurisdictions. The ‘White Space Matrix’ across major categories is a fundamental part of this Patent Overview Report.
Who can use the report?
Helps in mapping the big players in the broad spectrum of the technology
Helps in digging out white spaces that identify the technology gaps
Cognizant about the chronological developments in the technological field for the last 5 years
Finding alternative technical solutions to a problem
Helps in knowing the innovative focus of companies, industries, and countries
Spotting the new competitors
Legal assessors and representatives
Filing trends either for the overall number of patents, or just for certain groupings in the last 5 years
Financial and fiscal assessors and representatives
Forms the base for the evaluation of patents within the context of the control of organizational resources and accounting